NCT05236621Unknown3 期
A Multicenter, Open-Label, Single-Arm Clinical Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 入组人数
- 85
- 试验地点
- 23
- 主要终点
- Total Response Rate(ORR)
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of permadomide capsules developed by Qilu Pharmaceutical Co., LTD.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •1.Subjects diagnosed with multiple myeloma according to the diagnostic criteria of Chinese Multiple Myeloma Diagnosis and Treatment Guidelines (Revised in 2020); 2.Must be ≥ 18 years of age,male or female, if the subject is of childbearing age and should use effective contraceptive methods, the subject must agree to comply with all contraceptive requirements:
- •there are fertile women have to decide, at the same time take two reliable contraceptive methods (an effective contraceptive method is: tubal ligation, intrauterine contraceptive device, hormone (birth control pills, needles, patch, vaginal ring or implants) or partner vasectomy, another effective birth control method is: male or synthetic rubber condom, diaphragm or cervical cap). Unless hysterectomy is performed, effective contraception is required even if there is a history of infertility.
- •Fertile men must use rubber or synthetic condoms at all times during the use of this product and during sexual contact with fertile women within 28 days of discontinuation of this product, even if participants have successfully had a vasectomy.
- •Received at least two previous treatments (in different treatment regimens or the same regimen, including at least 2 cycles of lenalidomide and 2 cycles of proteasome inhibitors [such as bortezomib or ixazomib]) Relapse of multiple myeloma or ineffective to the last treatment (definition of last treatment ineffective: disease progression during the use of the treatment plan or disease progression within 60 days after the completion of the treatment plan), the last treatment plan is not limited;
- •Multiple myeloma subjects with measurable M protein, i.e., at least one of the following 3 assays:
- •Serum M protein≥0.5g/dL (5g/L);
- •Urine M protein≥200mg/24h;
- •Determination of serum free light chain: in the case of abnormal serum free light chain ratio, the level of involved free light chain is ≥10 mg/dL (100 mg/L);
- •Hematology meets the following conditions:
- •ANC≥1.0 x10^9/L (including ANC≥1.0x10^9/L supported by G-CSF); 2) PLT≥50 x10^9/L； 3) When plasma cells in bone marrow ≥50%, no specific requirements for neutrophil count, platelet ≥30 x10^9/L can be selected;
- •Liver and kidney function tests meet the following conditions:
- •TBIL ≤ 2.0mg/dL；
- •ALT、AST ≤ 3.0 x ULN； 3) Serum creatinine ≤ 3.0 mg/dL or creatinine clearance rate ≥ 30 mL/min;
- •Those who can accept and can use antithrombotic drugs, such as low molecular weight heparin sodium or aspirin;
- •Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2, expected survival ≥ 3 months;
- •There must be a washout period of ≥ 2 weeks (14 days) from the last treatment (excluding dexamethasone treatment);
- •Subjects voluntarily joined the study and signed a written informed consent.
排除标准
- •Subjects who cannot tolerate thalidomide, lenalidomide, pomalidomide and other types of drug treatment according to the judgment of the investigator.
- •Subjects who have had allergic reactions to immunomodulators similar to pomalidomide, dexamethasone or components contained in the drug;
- •Diagnosis of non-secretory MM (non-secretory subjects or subjects with a small amount of free light chain but less than 100mg/L) in multiple myeloma;
- •Subjects with active new thrombosis or unwilling to undergo antithrombotic therapy;
- •The subjects are suffering from other tumors at the same time or have a past history of tumors, or have undergone anti-tumor treatment (including major surgery) within the last 4 weeks, except for the following tumor diseases or those who have lived without tumors for ≥ 3 years so far: skin base Cell carcinoma, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, incidental histologic findings of prostate cancer (TNM clinical stage T1a or T1b), or treated prostate cancer;
- •Subjects suffering from central nervous system diseases and requiring treatment;
- •Subjects with peripheral neuropathy ≥ grade 3;
- •Subjects who need to use immunosuppressive or steroid drugs for a long time;
- •Known subjects with hepatitis B virus (HBV-DNA ≥ 1×10^3 copies/mL or HBV-DNA > 200 IU/mL) or hepatitis C virus (HCV) activity, or human immunodeficiency virus (HIV) ) serologically positive;
- •Subject has any of the following:
- •According to the NYHA classification standard, cardiac insufficiency grade 2 or above; 2) Myocardial infarction occurred within one year; 3) poorly controlled angina pectoris, including variant angina pectoris;
- •Subjects have serious infectious diseases at the same time;
- •Subjects planning to become pregnant or unable to take reliable contraceptive measures;
- •Women who are pregnant or breastfeeding;
- •Subjects who have received allogeneic hematopoietic stem cell transplantation within 12 months, or who have active graft-versus-host disease (GVHD) or who require immunosuppressive therapy after 12 months of allogeneic hematopoietic stem cell transplantation；
- •Those who participated in other clinical trials and received experimental drugs within one month before the first drug use.
研究组 & 干预措施
Permadomide + Low-Dose Dexamethasone
Experimental
Participants received 4 mg pomalidomide administered by mouth on Days 1 to 21 of each 28-day treatment cycle and 40 mg dexamethasone administered by mouth once per day on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression.
干预措施: Pomalidomide (Drug)
Permadomide + Low-Dose Dexamethasone
Experimental
Participants received 4 mg pomalidomide administered by mouth on Days 1 to 21 of each 28-day treatment cycle and 40 mg dexamethasone administered by mouth once per day on Days 1, 8, 15, and 22 of each 28-day cycle until disease progression.
干预措施: Dexamethasone (Drug)
结局指标
主要结局
Total Response Rate(ORR)
时间窗: From randomization through the study follow-up phase; up to the data cut-off of 1 December 2023; Maximum time on follow-up was 104 weeks.
Statistical analysis of ORR of primary efficacy will be based on IRC remission assessment results, as well as the investigator's remission assessment.Strict Complete Response (sCR) + Complete Response (CR) + Partial Response (PR) + Very Good PR (VGPR).
次要结局
- Overall survival(OS)(up to 104 weeks)
- Duration of remission(DoR)(The time from the first observation of at least partial remission (PR) to disease progression (PD) or death from any cause is whichever comes first, assessed up to 104 weeks.)
- Progression-free survival(PFS)(up to 104 weeks)
研究者
研究点 (23)
Loading locations...
相似试验
已完成
3 期
Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple MyelomaMultiple MyelomaNCT01324947Celgene74
已完成
4 期
A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic SeizuresEpilepsyNCT05533814Eisai Korea Inc.125
已完成
2 期
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer in JapanProstate CancerNCT05114746Novartis Pharmaceuticals94
已完成
2 期
A Study of Intravenous Perampanel in Japanese Participants With EpilepsySeizuresEpilepsyNCT03754582Eisai Co., Ltd.21
招募中
1 期
A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System LymphomaPCNSLNCT06554561Second Affiliated Hospital, School of Medicine, Zhejiang University43